Tecan Group AG (SWX:TECN)
135.40
-1.40 (-1.02%)
Apr 2, 2026, 5:30 PM CET
Tecan Group AG Employees
As of December 31, 2025, Tecan Group AG had 3,305 total employees, including 3,026 full-time and 279 part-time employees. The number of employees decreased by 36 or -1.08% compared to the previous year.
Employees
3,305
Change (1Y)
-36
Growth (1Y)
-1.08%
Revenue / Employee
278.74K CHF
Profits / Employee
-34.95K CHF
Market Cap
1.70B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 3,305 | -36 | -1.08% | 3,026 | 279 |
| Dec 31, 2024 | 3,341 | -232 | -6.49% | 3,074 | 267 |
| Dec 31, 2023 | 3,573 | 116 | 3.36% | 3,315 | 258 |
| Dec 31, 2022 | 3,457 | 166 | 5.04% | 3,206 | 251 |
| Dec 31, 2021 | 3,291 | 1,241 | 60.54% | 3,291 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Roche Holding AG | 103,249 |
| Novartis AG | 75,267 |
| Lonza Group AG | 19,771 |
| Galderma Group AG | 7,676 |
| Aevis Victoria | 4,731 |
| Medacta Group | 2,036 |
| SKAN Group AG | 1,504 |
| PolyPeptide Group AG | 1,440 |
Tecan Group AG News
- 3 days ago - Tecan Appoints Camila Japur As CFO - Nasdaq
- 17 days ago - Tecan Group AG (TCHBF) Full Year 2025 Earnings Call Highlights: Strategic Transformation Amidst ... - GuruFocus
- 17 days ago - Full Year 2025 Tecan Group AG Earnings Call And Capital Markets Day Transcript - GuruFocus
- 17 days ago - Tecan Group Slips To Loss In FY25; Issues FY26 Outlook, Backs Medium-term View - Nasdaq
- 6 months ago - Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook - GlobeNewsWire